1
|
Shafiee A, Beiky M, Mohammadi I, Rajai S, Jafarabady K, Moradi S, Beikmohamadi M, Teixeira AL. Effect of smoking on Brain-Derived Neurotrophic Factor (BDNF) blood levels: A systematic review and meta-analysis. J Affect Disord 2024; 349:525-533. [PMID: 38199418 DOI: 10.1016/j.jad.2024.01.082] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/11/2023] [Revised: 12/29/2023] [Accepted: 01/04/2024] [Indexed: 01/12/2024]
Abstract
BACKGROUND Brain-Derived Neurotrophic Factor (BDNF) is a neurotrophin that plays a crucial role in neuronal survival and plasticity. Previous studies have suggested that smoking may influence BDNF levels, but the findings have been inconsistent. METHODS A comprehensive search of electronic databases was conducted to identify relevant studies. Inclusion criteria were applied to select studies that investigated the relationship between smoking and blood levels of BDNF. A random-effects model was used to estimate the overall effect size. RESULTS A total of 23 studies were included. The meta-analysis revealed a significant association between smoking and increased blood levels of BDNF (standardized mean difference [SMD] = -0.38, 95 % confidence interval [CI] 0.15 to 0.62, p = 0.002). Subgroup analyses based on BDNF source showed a significant increase in plasma-derived BDNF levels (SMD = 1.02, 95 % CI 0.50 to 1.53, p = 0.0001), while no significant difference was observed in serum-derived BDNF levels (SMD = 0.02, 95 % CI -0.19 to 0.22, p = 0.87). The pooled analysis revealed a non-significant difference in blood levels of BDNF between former smokers and non-smokers (random-effects model, SMD = 0.21, 95 % CI -0.04 to 0.46, p = 0.1). CONCLUSION Smokers exhibited significantly higher plasma levels of BDNF compared to non-smokers. Further research is needed to elucidate the underlying mechanisms and explore the potential therapeutic implications of targeting BDNF in smoking.
Collapse
Affiliation(s)
- Arman Shafiee
- Department of Psychiatry and Mental Health, Alborz University of Medical Sciences, Karaj, Iran; Student Research Committee, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran.
| | - Maryam Beiky
- Student Research Committee, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran
| | - Ida Mohammadi
- School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Shahryar Rajai
- School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Kyana Jafarabady
- Student Research Committee, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran
| | - Shayan Moradi
- School of Dentistry, Tehran University of Medical Sciences, Tehran, Iran
| | - Mahya Beikmohamadi
- Student Research Committee, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran
| | - Antonio Lucio Teixeira
- Neuropsychiatry Program, Department of Psychiatry and Behavioral Sciences, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USA
| |
Collapse
|
2
|
Koyya P, Manthari RK, Pandrangi SL. Brain-Derived Neurotrophic Factor - The Protective Agent Against Neurological Disorders. CNS & NEUROLOGICAL DISORDERS DRUG TARGETS 2024; 23:353-366. [PMID: 37287291 DOI: 10.2174/1871527322666230607110617] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/28/2023] [Revised: 05/19/2023] [Accepted: 05/29/2023] [Indexed: 06/09/2023]
Abstract
The burden of neurological illnesses on global health is significant. Our perception of the molecular and biological mechanisms underlying intellectual processing and behavior has significantly advanced over the last few decades, laying the groundwork for potential therapies for various neurodegenerative diseases. A growing body of literature reveals that most neurodegenerative diseases could be due to the gradual failure of neurons in the brain's neocortex, hippocampus, and various subcortical areas. Research on various experimental models has uncovered several gene components to understand the pathogenesis of neurodegenerative disorders. One among them is the brain-derived neurotrophic factor (BDNF), which performs several vital functions, enhancing synaptic plasticity and assisting in the emergence of long-term thoughts. The pathophysiology of some neurodegenerative diseases, including Alzheimer's, Parkinson's, Schizophrenia, and Huntington's, has been linked to BDNF. According to numerous research, high levels of BDNF are connected to a lower risk of developing a neurodegenerative disease. As a result, we want to concentrate on BDNF in this article and outline its protective role against neurological disorders.
Collapse
Affiliation(s)
- Prathyusha Koyya
- Department of Biotechnology, GITAM School of Science, Gandhi Institute of Technology and Management (Deemed to be University), Visakhapatnam-530045, Andhra Pradesh, India
| | - Ram Kumar Manthari
- Department of Biotechnology, GITAM School of Science, Gandhi Institute of Technology and Management (Deemed to be University), Visakhapatnam-530045, Andhra Pradesh, India
| | - Santhi Latha Pandrangi
- Department of Biochemistry and Bioinformatics, GITAM School of Science, Gandhi Institute of Technology and Management (Deemed to be University), Visakhapatnam- 530045, Andhra Pradesh, India
| |
Collapse
|
3
|
Izuo N, Miyanishi H, Nishizawa D, Fujii T, Hasegawa J, Sato N, Tanioka F, Sugimura H, Ikeda K, Nitta A. DNA methylation status of SHATI/NAT8L promoter in the blood of cigarette smokers. Neuropsychopharmacol Rep 2023; 43:570-575. [PMID: 37668111 PMCID: PMC10739067 DOI: 10.1002/npr2.12373] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2023] [Revised: 07/15/2023] [Accepted: 07/23/2023] [Indexed: 09/06/2023] Open
Abstract
AIMS Cigarette smoking is a preventable risk factor for various diseases such as cancer, ischemic stroke, cardiac stroke, and chronic obstructive pulmonary disease. Smoking cessation is of great importance not only for individual smokers but also for social health. Regarding current cessation therapies, the effectiveness of nicotine replacement is limited, and the cost of varenicline medication is considerable. Thus, a method for screening smokers who are responsive to cessation therapy based on the therapeutic effectiveness is required. Peripheral biomarkers reflecting smoking dependence status are necessary to establish a method for achieving effective cessation therapy. METHODS Methylation status of smokers' blood DNA was evaluated focusing on SHATI/NAT8L, an addiction-related gene. Eight CpG sites in SHATI/NAT8L were quantified by pyrosequencing. RESULTS There was no difference in the methylation status of this gene between smokers (n = 129) and non-smokers (n = 129) at all CpG sites. No correlations between the methylation status of SHATI/NAT8L and indicators of smoking dependence were found. CONCLUSIONS Although the present study found no significance in the DNA methylation of SHATI/NAT8L among smokers, the exploration of predictable peripheral biomarkers for the effectiveness of smoking cessation therapy is required.
Collapse
Affiliation(s)
- Naotaka Izuo
- Department of Pharmaceutical Therapy and Neuropharmacology, Faculty of Pharmaceutical SciencesUniversity of ToyamaToyamaJapan
| | - Hajime Miyanishi
- Department of Pharmaceutical Therapy and Neuropharmacology, Faculty of Pharmaceutical SciencesUniversity of ToyamaToyamaJapan
| | - Daisuke Nishizawa
- Addictive Substance ProjectTokyo Metropolitan Institute of Medical ScienceTokyoJapan
| | - Takuma Fujii
- Department of Pharmaceutical Therapy and Neuropharmacology, Faculty of Pharmaceutical SciencesUniversity of ToyamaToyamaJapan
| | - Junko Hasegawa
- Addictive Substance ProjectTokyo Metropolitan Institute of Medical ScienceTokyoJapan
| | - Naomi Sato
- Department of Clinical NursingHamamatsu University School of MedicineShizuokaJapan
- Department of Tumor PathologyHamamatsu University School of MedicineShizuokaJapan
| | - Fumihiko Tanioka
- Department of PathologyIwata City HospitalShizuokaJapan
- Present address:
KDP Pathology Clinic2‐30‐14 Hirosawa Nakaku HamamatsuShizuokaJapan
| | - Haruhiko Sugimura
- Department of Tumor PathologyHamamatsu University School of MedicineShizuokaJapan
- Present address:
Sasaki Institute, Sasaki Foundation2‐2 Kandasurugadai, Chiyoda‐KuTokyo101‐0062Japan
| | - Kazutaka Ikeda
- Addictive Substance ProjectTokyo Metropolitan Institute of Medical ScienceTokyoJapan
| | - Atsumi Nitta
- Department of Pharmaceutical Therapy and Neuropharmacology, Faculty of Pharmaceutical SciencesUniversity of ToyamaToyamaJapan
| |
Collapse
|
4
|
Wang T, Li T, Hao S, Han Y, Cai Y. Association of plasma BDNF levels with different stages of Alzheimer's disease: a cross-sectional study. Neurol Res 2023; 45:234-240. [PMID: 36453692 DOI: 10.1080/01616412.2022.2129760] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/02/2022]
Abstract
BACKGROUND Growing evidence shows that the expression of brain-derived neurotrophic factor (BDNF) is altered in the peripheral blood of participants with Alzheimer's disease (AD). It is unclear, however, whether altered BDNF expression is also observed in the early stages of AD. METHODS In the present study, 138 normal controls (NC), 57 participants with subjective cognitive decline (SCD), and 37 participants with amnestic mild cognitive impairment (aMCI) and AD were included. Plasma BDNF protein levels were assessed using a commercial multiplex Luminex-based kit. Patient samples were also probed for the presence of BDNF gene variant rs6265. RESULTS Pairwise comparisons between the groups showed that there was not a significant difference in BDNF levels when comparing SCD with NC and when comparing SCD with aMCI/AD, but BDNF levels in aMCI/AD samples were increased when compared with NC samples. For models differentiating clinical groups, discriminant analysis was performed by including education, APOE genotype, and BDNF levels in the model. This approach distinguishes participants with SCD (AUC = 0.630) and aMCI/AD (AUC = 0.665) from NC. CONCLUSION Our results suggest that expression of BDNF in plasma is altered at the clinical stage of AD.
Collapse
Affiliation(s)
- Ting Wang
- Department of Biobank, Xuanwu Hospital of Capital Medical University, Beijing, China.,National Clinical Research Center for Geriatric Disorders, Xuanwu Hospital of Capital Medical University, Beijing, China
| | - Taoran Li
- Department of Neurology, Xuanwu Hospital of Capital Medical University, Beijing, China
| | - Shuwen Hao
- Department of Biobank, Xuanwu Hospital of Capital Medical University, Beijing, China.,National Clinical Research Center for Geriatric Disorders, Xuanwu Hospital of Capital Medical University, Beijing, China
| | - Ying Han
- National Clinical Research Center for Geriatric Disorders, Xuanwu Hospital of Capital Medical University, Beijing, China.,Department of Neurology, Xuanwu Hospital of Capital Medical University, Beijing, China.,Center of Alzheimer's Disease, Beijing Institute for Brain Disorders, Xuanwu Hospital of Capital Medical University, Beijing, China
| | - Yanning Cai
- Department of Biobank, Xuanwu Hospital of Capital Medical University, Beijing, China.,National Clinical Research Center for Geriatric Disorders, Xuanwu Hospital of Capital Medical University, Beijing, China.,Beijing Geriatric Medical Research Center, Xuanwu Hospital of Capital Medical University, Beijing, China
| |
Collapse
|
5
|
Initial and ongoing tobacco smoking elicits vascular damage and distinct inflammatory response linked to neurodegeneration. Brain Behav Immun Health 2023; 28:100597. [PMID: 36817509 PMCID: PMC9931921 DOI: 10.1016/j.bbih.2023.100597] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2022] [Revised: 12/07/2022] [Accepted: 01/21/2023] [Indexed: 01/30/2023] Open
Abstract
Tobacco smoking is strongly linked to vascular damage contributing to the development of hypertension, atherosclerosis, as well as increasing the risk for neurodegeneration. Still, the involvement of the innate immune system in the development of vascular damage upon chronic tobacco use before the onset of clinical symptoms is not fully characterized. Our data provide evidence that a single acute exposure to tobacco elicits the secretion of extracellular vesicles expressing CD105 and CD49e from endothelial cells, granting further recognition of early preclinical biomarkers of vascular damage. Furthermore, we investigated the effects of smoking on the immune system of healthy asymptomatic chronic smokers compared to never-smokers, focusing on the innate immune system. Our data reveal a distinct immune landscape representative for early stages of vascular damage in clinically asymptomatic chronic smokers, before tobacco smoking related diseases develop. These results indicate a dysregulated immuno-vascular axis in chronic tobacco smokers that are otherwise considered as healthy individuals. The distinct alterations are characterized by increased CD36 expression by the blood monocyte subsets, neutrophilia and increased plasma IL-18 and reduced levels of IL-33, IL-10 and IL-8. Additionally, reduced levels of circulating BDNF and elevated sTREM2, which are associated with neurodegeneration, suggest a considerable impact of tobacco smoking on CNS function in clinically healthy individuals. These findings provide profound insight into the initial and ongoing effects of tobacco smoking and the potential vascular damage contributing to neurodegenerative disorders, specifically cerebrovascular dysfunction and dementia.
Collapse
|
6
|
Jemni M, Zaman R, Carrick FR, Clarke ND, Marina M, Bottoms L, Matharoo JS, Ramsbottom R, Hoffman N, Groves SJ, Gu Y, Konukman F. Exercise improves depression through positive modulation of brain-derived neurotrophic factor (BDNF). A review based on 100 manuscripts over 20 years. Front Physiol 2023; 14:1102526. [PMID: 36969600 PMCID: PMC10030936 DOI: 10.3389/fphys.2023.1102526] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2022] [Accepted: 01/30/2023] [Indexed: 03/29/2023] Open
Abstract
The aim of this review was to explore the relevant neurobiology and the association between peripheral levels of brain-derived neurotrophic factor (BDNF) and acute and short to long-term exercise regimes, as well as its relation to depression and antidepressant treatment. A 20-year literature search was conducted. The screening process resulted in 100 manuscripts. Antidepressants as well as acute exercise, particularly high-intensity, elevates BDNF in healthy humans and clinical populations, as evidenced from aerobic and resistance-based studies. Although exercise is increasingly recognised in the management of depression, acute and short-term exercise studies have failed to establish a relationship between the severity of depression and changes in peripheral BDNF. The latter rapidly returns to baseline, possibly indicating a quick re-uptake by the brain, aiding its neuroplasticity functions. The timescale of administration needed for the antidepressants to stimulate biochemical changes is longer than similar increases with acute exercise.
Collapse
Affiliation(s)
- Monèm Jemni
- Faculty of Physical Education, Ningbo University, Ningbo, Zhejiang, China
- The Carrick Institute of Neuroscience, Cape Canaveral, FL, United States
- Centre for Mental Health Research in association with The University of Cambridge, Cambridge, United Kingdom
- *Correspondence: Monèm Jemni, ; Yaodong Gu,
| | - Rashid Zaman
- Centre for Mental Health Research in association with The University of Cambridge, Cambridge, United Kingdom
- Department of Psychiatry, The University of Cambridge, Cambridge, United Kingdom
| | - Frederick Robert Carrick
- The Carrick Institute of Neuroscience, Cape Canaveral, FL, United States
- Centre for Mental Health Research in association with The University of Cambridge, Cambridge, United Kingdom
- University of Central Florida College of Medicine, Orlando, FL, United states
- MGH Institute of Health Professions, Boston, MA, United States
| | - Neil David Clarke
- Centre for Sport, Exercise and Life Sciences, Coventry University, Coventry, United Kingdom
| | - Michel Marina
- Institut Nacional d'Educació Física de Catalunya (INEFC), Sport Performance, Barcelona, Spain
| | - Lindsay Bottoms
- School of Life and Medical Sciences, University of Hertfordshire, Hatfield, Hertfordshire, United Kingdom
| | | | - Roger Ramsbottom
- Sport and Health Sciences, Faculty of Health and Life Sciences, Oxford Brookes University, Oxford, United Kingdom
| | - Norman Hoffman
- The Carrick Institute of Neuroscience, Cape Canaveral, FL, United States
| | - Shad James Groves
- The Carrick Institute of Neuroscience, Cape Canaveral, FL, United States
| | - Yaodong Gu
- Faculty of Physical Education, Ningbo University, Ningbo, Zhejiang, China
- *Correspondence: Monèm Jemni, ; Yaodong Gu,
| | - Ferman Konukman
- Department of Physical Education, College of Education, Qatar University, Doha, Qatar
| |
Collapse
|
7
|
Grieder TE, Yee M, Vargas-Perez H, Maal-Bared G, George S, Ting-A-Kee R, George O, van der Kooy D. Administration of brain-derived neurotrophic factor in the ventral tegmental area produces a switch from a nicotine nondependent D1R-mediated motivational state to a nicotine dependent-like D2R-mediated motivational state. Eur J Neurosci 2021; 55:714-724. [PMID: 34963197 DOI: 10.1111/ejn.15579] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2021] [Revised: 12/15/2021] [Accepted: 12/21/2021] [Indexed: 11/27/2022]
Abstract
Brain-derived neurotrophic factor (BDNF) has been implicated in the transition from a nondependent motivational state to a drug-dependent and -withdrawn motivational state. Chronic nicotine can increase BDNF in the rodent brain and is associated with smoking severity in humans; however, it is unknown whether this increased BDNF is linked functionally to the switch from a nicotine-nondependent to a nicotine-dependent state. We used a place conditioning paradigm to measure the conditioned responses to nicotine, showing that a dose of acute nicotine that nondependent male mice find aversive is found rewarding in chronic nicotine-treated mice experiencing withdrawal. A single BDNF injection in the ventral tegmental area (in the absence of chronic nicotine treatment) caused mice to behave as if they were nicotine-dependent and in withdrawal, switching the neurobiological substrate mediating the conditioned motivational effects from dopamine D1 receptors to D2 receptors. Quantification of gene expression of BDNF and its receptor, tropomyosin-receptor-kinase B (TrkB), revealed an increase in TrkB mRNA but not BDNF mRNA in the VTA in nicotine-dependent and -withdrawn mice. These results suggest that BDNF signaling in the VTA is a critical neurobiological substrate for the transition to nicotine dependence. The modulation of BDNF signaling may be a promising new pharmacological avenue for the treatment of addictive behavior.
Collapse
Affiliation(s)
- Taryn E Grieder
- Department of Molecular Genetics and Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada
| | - Mandy Yee
- Department of Molecular Genetics and Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada
| | - Hector Vargas-Perez
- The Nierika Intercultural Medicine Institute, Ocuilan, Estado de México, México
| | - Geith Maal-Bared
- Department of Molecular Genetics and Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada
| | - Susan George
- Department of Molecular Genetics and Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada
| | - Ryan Ting-A-Kee
- Department of Molecular Genetics and Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada
| | - Olivier George
- Department of Psychiatry, UCSD School of Medicine, La Jolla, California, USA
| | - Derek van der Kooy
- Department of Molecular Genetics and Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada
| |
Collapse
|